Onkologie. 2012:6(4):190-194

Aspects of ortopedical oncology

Dagmar Adámková Krákorová
Klinika komplexní onkologické péče, Masarykův onkologický ústav Brno

Bone sarcomas are extremely rare neoplasms. Early diagnosis and effective treatment are significant for the therapy achievment. According

to the high specialization, multidisciplinary treatments planning by an experienced team is mandatory in all cases of bone sarcoma.

Multimodal therapy is needed in case of high grade osteosarcoma and Ewing´s sarcoma/PNET, survival in patients with localised disease

has improved dramatically due to the advent of effective multiagent chemotherapy regimens. Surgery is a standard treatment for patients

with low grade osteosarcoma and chondrosarcoma, complemented by radiation therapy in selected cases.

Keywords: bone sarcomas, multidisciplinary treatment, survival

Published: October 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adámková Krákorová D. Aspects of ortopedical oncology. Onkologie. 2012;6(4):190-194.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Isakoff MF, Harris MJ, Beghart MC, Grier HE. Bone Sarcomas in: Cancer in Adolescents and Young Adults, editors Bleyer WA, Barr RD. Springer-Verlag Berlin Heidelberg New York 2007; 12: 203-218. Go to original source...
    2. Bleyer WA, O´Leary M, Barr R, Ries (eds). Cancer epidemiology in Older Adolescents and Young Adults 15 to 29 years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, 2006, NIH Pub. No 06-5767, Bethesda MD, www.seer.cancer.gov/publications.
    3. Martin M Malawer, Lee J Helman, Brian O´ Sullivan. Sarcomas of Bone. In De Vita VT, Hellmann S, Rosenberg SA, et al. Cancer Principles and Practise Of Oncology, (8. th. ed). Philadelphia: Lippincot Williams and Wilkins 2008: 1794-1812.
    4. Cancer Management: A Multidisciplinary Approach, 12th edition, edited by Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, 2009; 21: 569-583.
    5. NCCN Clinical Practise Guidlines in Oncology, Bone cancer, V. 2/2012.
    6. Bielack SS, Bielack KB, Delling G, et al. Prognostic factors in high grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790. Go to original source... Go to PubMed...
    7. Kovar H, Le Deley M, Delattre O, et al. Impact of EWS/FLI1 fusion type on disease progression in Ewing´s sarcoma: prospective results from the cooperative Euro-E.W.I.N.G.99 trial. Proc Annu Meet Am Assoc Cancer Res 2009: abstr 5680.
    8. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007; 19(4): 341-346. Go to original source... Go to PubMed...
    9. De Laney TF, et al. Radiotherapy for local control of osteosarcoma. Int J radiat Oncol Biol Phys 2005; 61: 492-498. Go to original source... Go to PubMed...
    10. Bacci G, Lonhgi A, Beroni F, et al. Primary high grade osteosarcoma: comparsion between preadolescent and older patients. Journal of Pediatr Hematol Oncology 2005; 27: 129-134. Go to original source... Go to PubMed...
    11. EURAMOS. www.ctu.mrc.ac.uk/euramos.
    12. Harting ML, Blakely ML. Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg 2006; 15(1): 25-29. Go to original source... Go to PubMed...
    13. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patiens treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99(2): 112-128. Go to original source... Go to PubMed...
    14. EWING 2008 treatment manual, version 1-010607, ewing@uni-muenster.de.
    15. www.mou.cz/pro odborníky/léčebné protokoly/sarkomy kostí.
    16. Naomi J Balamuth, Richard B Wormer. Ewing´s sarcoma. The Lancet Oncology 2010; 11: 184-192. Go to original source... Go to PubMed...
    17. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcoma (Ewing´s sarcoma and osteosarcoma), Expert Opin. Investig. Drugs 2008; 17(11): 1703-1715. Go to original source... Go to PubMed...
    18. Mora J, Cruz CO, Parareda A, et al. Treatment of relapsed/ refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009; 31(10): 723-729. Go to original source... Go to PubMed...
    19. Bond M, Bernstein M, Pappo A, et al. A phase II study of imanitib mesylate in children with refractory or relapsed solid tumors: a Children´s Oncology Group study. Pediatr Blood Cancer 2008; 50: 254-58. Go to original source... Go to PubMed...
    20. Müller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only adjuvant treatment in high-gradosteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl. Cancer Inst 2007; 99: 112-128. Go to original source... Go to PubMed...
    21. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves survival - a report from the Childrens Oncology Group. J Clin Oncol 2008; 26(4): 633-638. Go to original source... Go to PubMed...
    22. Zapletalova D, André N, Deak L, et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology 2012; 82(5): 249-260. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.